You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Patients with advanced urothelial cancer characterized by HRAS mutations saw their tumors shrink after treatment with Kura Oncology's lead investigational drug tipifarnib in a Phase II proof-of-concept study.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.